Chemistry:Tramadol

From HandWiki
Short description: Medication of the opioid type
Tramadol
Tramadol as a racemic mixture.svg
Tramadol-based-on-xtal-3D-bs-17.png
Clinical data
Pronunciationtra' ma doll
Trade namesUltram, Zytram, Ralivia, others[1]
AHFS/Drugs.comMonograph
MedlinePlusa695011
License data
Pregnancy
category
Dependence
liability		Low-moderate[3]
Routes of
administration		By mouth, intravenous (IV), intramuscular (IM), rectal
Drug classOpioid analgesic[4]
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability70–75% (by mouth), 77% (rectal), 100% (IM)[8]
Protein binding20%[3]
MetabolismLiver-mediated demethylation and glucuronidation via CYP2D6 & CYP3A4[8][9]
MetabolitesO-desmethyltramadol, N-desmethyltramadol
Onset of actionLess than 1 hour (by mouth)[3]
Elimination half-life6.3 ± 1.4 h[9]
Duration of action6 hours[10]
ExcretionUrine (95%)[11]
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
FormulaC16H25NO2
Molar mass263.381 g·mol−1
3D model (JSmol)
Melting point180 to 181 °C (356 to 358 °F)
 ☒N☑Y (what is this?)  (verify)

Tramadol, sold under the brand name Ultram among others,[1] is an opioid pain medication and a serotonin–norepinephrine reuptake inhibitor (SNRI) used to treat moderately severe pain.[3][12] When taken by mouth in an immediate-release formulation, the onset of pain relief usually begins within an hour.[3] It is also available by injection.[13] It is available in combination with paracetamol (acetaminophen).

As is typical of opioids, common side effects include constipation, itchiness, and nausea.[3] Serious side effects may include hallucinations, seizures, increased risk of serotonin syndrome, decreased alertness, and drug addiction.[3] A change in dosage may be recommended in those with kidney or liver problems.[3] It is not recommended in those who are at risk of suicide or in those who are pregnant.[3][13] While not recommended in women who are breastfeeding, those who take a single dose should not generally have to stop breastfeeding.[14] Tramadol is converted in the liver to O-desmethyltramadol (desmetramadol), an opioid with a stronger affinity for the μ-opioid receptor.[3][15]

Tramadol was patented in 1972 and launched under the name "Tramal" in 1977 by the West German pharmaceutical company Grünenthal GmbH.[12][16] In the mid-1990s, it was approved in the United Kingdom and the United States.[12] It is available as a generic medication and marketed under many brand names worldwide.[1][3] In 2021, it was the 41st most commonly prescribed medication in the United States, with more than 15 million prescriptions.[17][18]

Medical uses

Generic tramadol HCl tablets marketed by Amneal Pharmaceuticals
Tramadol HCl for injection

Tramadol is used primarily to treat mild to severe pain, both acute and chronic.[19][20] There is moderate evidence for use as a second-line treatment for fibromyalgia but it is not FDA approved for this use.[21] Its use is approved for treatment of fibromyalgia as a secondary painkiller by the NHS.[22]

Its analgesic effects take approximately an hour to be realized, and it takes from two to four hours to reach peak effect after oral administration with an immediate-release formulation.[19][20] On a dose-by-dose basis, tramadol has about one-tenth the potency of morphine (thus 100 mg is commensurate with 10 mg morphine but may vary) and is practically equally potent when compared with pethidine and codeine.[23] For moderate pain, its effectiveness is roughly equivalent to that of codeine in low doses and hydrocodone at very high doses. For severe pain it is less effective than morphine.[19]

Pain reducing effects last approximately six hours. The potency of analgesia varies considerably as it depends on an individual's genetics. People with specific variants of CYP2D6 enzymes may not produce adequate amounts of the active metabolite (desmetramadol) for effective pain control.[11][19]

Sleep medicine physicians sometimes prescribe tramadol (or other opiate medications) for refractory restless legs syndrome (RLS);[24][25] that is, RLS that does not respond adequately to treatment with first-line medications such as dopamine agonists (like pramipexole) or alpha-2-delta (α2δ) ligands (gabapentinoids), often due to augmentation.[26]

Contraindications

Individuals with certain genetic variations of CYP2D6 enzymes, which convert tramadol into an inactive molecule, may not experience enough pain relief from tramadol.[11][19] These genetic polymorphisms are not currently routinely tested for in clinical practice.[27]

Pregnancy and lactation

Tramadol's use in pregnancy is generally avoided, as it may cause some reversible withdrawal effects in the newborn.[28] A small prospective study in France found, while an increased risk of miscarriages existed, no major malformations were reported in the newborn.[28] Its use during lactation is also generally advised against, but a small trial found that infants breastfed by mothers taking tramadol were exposed to about 2.88% of the dose the mothers were taking. No evidence of this dose harming the newborn was seen.[28]

Labor and delivery

Its use as an analgesic during labor is not advised due to its long onset of action (1 hour).[28] The ratio of the mean concentration of the drug in the fetus compared to that of the mother when it is given intramuscularly for labor pains has been estimated to be 1:94.[28]

Children

Its use in children is generally advised against, although it may be done under the supervision of a specialist.[19] On 21 September 2015, the FDA started investigating the safety of tramadol in use in persons under the age of 17. The investigation was initiated because some of these people have experienced slowed or difficult breathing.[29] The FDA lists age under 12 years old as a contraindication.[30][31]

Elderly

The risk of opioid-related adverse effects such as respiratory depression, falls, cognitive impairment and sedation is increased.[19] Tramadol may interact with other medications and increase the risk for adverse events.[27]

Liver and kidney failure

The drug should be used with caution in those with liver or kidney failure, due to metabolism in the liver (to the active molecule desmetramadol) and elimination by the kidneys.[19]

Side effects

The most common adverse effects of tramadol include nausea, dizziness, dry mouth, indigestion, abdominal pain, vertigo, vomiting, constipation, drowsiness, and headache.[32][33] Other side effects may result from interactions with other medications. Tramadol has the same dose-dependent adverse effects as morphine including respiratory depression.[34]

Main side effects of tramadol: Red color denotes more serious effects, requiring immediate contact with health provider.[4]

Dependence and withdrawal

Long-term use of high doses of tramadol causes physical dependence and withdrawal syndrome.[35] These include both symptoms typical of opioid withdrawal and those associated with serotonin–norepinephrine reuptake inhibitor (SNRI) withdrawal; symptoms include numbness, tingling, paresthesia, and tinnitus.[36] Psychiatric symptoms may include hallucinations, paranoia, extreme anxiety, panic attacks, and confusion.[37] In most cases, tramadol withdrawal will set in 12–20 hours after the last dose, but this can vary.[36] Tramadol withdrawal typically lasts longer than that of other opioids. Seven days or more of acute withdrawal symptoms can occur as opposed to typically 3 or 4 days for other codeine analogues.[36]

Overdose

The clinical presentation in overdose cases can vary but typically includes neurological, cardiovascular, and gastrointestinal manifestations.[38] The predominant neurological symptoms are seizures and altered levels of consciousness, ranging from somnolence to coma. Seizures are particularly notable due to tramadol's lowering of the seizure threshold, occurring in approximately half of acute poisoning cases.[39] Patients often exhibit tachycardia and mild hypertension. Gastrointestinal disturbances such as nausea and vomiting are common, and agitation, anxiety, and cold and clammy skin may also be present.[40]

While less common, severe complications like respiratory depression and serotonin syndrome can occur, particularly in polydrug overdoses involving other CNS depressants (such as Benzodiazepines, Opioids, and Alcohol) and agents with serotonergic activity.[41][42] Additionally, Individuals with genetic variations leading to CYP2D6 enzyme duplication (rapid metabolizers) may have an increased risk of adverse effects, due to faster conversion of tramadol to its active metabolite.[43]

Acute tramadol overdose is generally not life-threatening, with most fatalities resulting from polysubstance overdose.[44] Management includes cardiovascular monitoring, activated charcoal administration, hydration, and treatment of seizures.[45] Naloxone, an opioid antagonist, can partially reverse some effects of tramadol overdose, particularly respiratory depression. However, its use may increase the risk of seizures due to unopposed alpha-adrenergic stimulation.[19] For suspected serotonin syndrome, cyproheptadine, a serotonin antagonist, is considered an effective antidote.[41]

The incidence of tramadol-related overdose deaths has been on the rise in certain regions. For instance, Northern Ireland has reported an increased frequency of such cases.[46] In 2013, England and Wales recorded 254 tramadol-related deaths, while Florida reported 379 cases in 2011.[47][48] In 2011, 21,649 emergency room visits in the United States were related to tramadol.[49] The likely explanation for these observations is due to increase in frequency of prescriptions and use due to easier access due to lighter regulatory scheduling by authorities[50] but this is starting to change. In 2021, Health Canada announced tramadol would be added to Schedule I of the Controlled Drugs and Substances Act and to the Narcotic Control Regulations due to tramadol being suspected of having contributed to 18 reported deaths in Canada between 2006 and 2017.[51]

Interactions

Tramadol Hydrochloride (50mg) capsules made by Bristol Laboratories and provided by a pharmacy in England

Tramadol can have pharmacodynamic, pharmacokinetic, and pharmacogenetic interactions.

Tramadol is metabolized by CYP2D6 enzymes which contribute to the metabolism of approximately 25% of all medications.[52] Any medications with the ability to inhibit or induce these enzymes may interact with tramadol. These include common antiarrhythmics, antiemetics, antidepressants (sertraline, paroxetine, and fluoxetine in particular),[53] antipsychotics, analgesics, and tamoxifen.[54]

Due to tramadol's serotonergic effects, tramadol has the potential to contribute to the development of an acute or chronic hyper-serotonin state called serotonin syndrome when used concurrently with other pro-serotonergic medications such as antidepressants (SSRI, SNRI, Tricyclics, MAOIs), antipsychotics, triptans, cold medications containing dextromethorphan, and some herbal products such as St. John's wort.[54][55]

Concurrent use of 5-HT3 antagonists such as ondansetron, dolasetron, and palonosetron may reduce the effectiveness of both drugs.[56]

Tramadol also acts as an opioid agonist and thus can increase the risk for side effects when used with other opioid and opioid-containing analgesics (such as morphine, pethidine, tapentadol, oxycodone, fentanyl, and Tylenol 3).[57]

Tramadol increases the risk for seizures by lowering the seizure threshold. Using other medications that lower seizure threshold - such as antipsychotic medications, Bupropion (an anti-depressant and smoking cessation drug), and amphetamines - can further increases this risk.[58]

Pharmacology

Mechanism of action

Tramadol induces analgesic effects through a variety of different targets on the noradrenergic system, serotoninergic system and opioid receptors system.[59] Tramadol exists as a racemic mixture, the positive enantiomer inhibits serotonin reuptake while the negative enantiomer inhibits noradrenaline re-uptake, by binding to and blocking the transporters.[60][10] Tramadol has also been shown to act as a serotonin releasing agent. Both enantiomers of tramadol are agonists of the μ-opioid receptor and its M1 metabolite, O-desmetramadol, is also a μ-opioid receptor agonist but is 6 times more potent than tramadol itself.[61] All these effects work synergistically to induce analgesia.

Site Tramadol DSMT Species Ref
DOR >10,000
57,600–100,000		 ≥2,900
690 (+))		 Human
Rat		 [62][63][64]
[65][66]
KOR >10,000
42,700–81,000		 ≥450
1,800 (+))		 Human
Rat		 [62][63][64]
[65][66]
NET 14,600
785		 1,080 (−) (IC50)
>860 (IC50)		 Human
Rat		 [15]
[65][15]
5-HT1A >20,000 >20,000 Rat [64]
5-HT2A >20,000 >20,000 Rat [64]
5-HT2C 1,000 (IC50) 1,300 (IC50) Rat [67][68]
5-HT3 >20,000 >20,000 Rat [64]
NK1 IA ? Rat [69][70]
M1 >20,000
3,400 (IC50)		 >20,000
2,000 (IC50)		 Rat
Multiple		 [64]
[71][72]
M2 ND ND ND ND
M3 1,000 (IC50) IA Human [72][73]
M4 ND ND ND ND
M5 ND ND ND ND
α7 7,400 ND Chicken [74]
σ1 >10,000 ND Rat [75][76]
σ2 >10,000 ND Rat [75]
NMDAR 16,400 (IC50) 16,500 (IC50) Human [77]
NMDAR
(MK-801)		 >20,000 >20,000 Rat [64]
GABAA >100,000 (IC50) >100,000 (IC50) Human [77]
GlyR >100,000 (IC50) >100,000 (IC50) Human [77]
TRPA1 100–
10,000 (SI)		 1,000–
10,000 (SI)		 Human [78]
TRPV1 >10,000 (IC50) >10,000 (IC50) Human [78][79]
Values are Ki (nM), unless otherwise noted. The smaller the value, the more strongly the drug binds to the site.

Tramadol and mono-
amine reuptake/release[80]
Action Value
5-HT reuptake 1,820
5-HT release >10,000
NE reuptake 2,770
NE release >10,000
DA reuptake >10,000
DA release >10,000
Values for reuptake inhibition are Ki (nM) and for release induction are EC50 (nM)

Tramadol has been found to possess these actions:[81][82][60]

Tramadol acts on the opioid receptors through its major active metabolite desmetramadol, which has as much as 700-fold higher affinity for the MOR relative to tramadol.[15] Moreover, tramadol itself has been found to possess no efficacy in activating the MOR in functional activity assays, whereas desmetramadol activates the receptor with high intrinsic activity (Emax equal to that of morphine).[83][15][84] As such, desmetramadol is exclusively responsible for the opioid effects of tramadol.[85] Both tramadol and desmetramadol have pronounced selectivity for the MOR over the DOR and KOR in terms of binding affinity.[64][63][66]

Tramadol is well-established as an SRI.[81][82] In addition, a few studies have found that it also acts as a serotonin releasing agent (1–10 μM), similar in effect to fenfluramine.[86][87][88][89] The serotonin releasing effects of tramadol could be blocked by sufficiently high concentrations of the serotonin reuptake inhibitor 6-nitroquipazine, which is in accordance with other serotonin releasing agents such as fenfluramine and MDMA.[86][88][89] However, two more recent studies failed to find a releasing effect of tramadol at respective concentrations up to 10 and 30 μM.[90][89][80] In addition to serotonergic activity, tramadol is also a norepinephrine reuptake inhibitor.[81][82] It is not a norepinephrine releasing agent.[91][92][93][80] Tramadol does not inhibit the reuptake or induce the release of dopamine.[91][80]

A positron emission tomography imaging study found that single oral 50-mg and 100-mg doses of tramadol to human volunteers resulted in 34.7% and 50.2% respective mean occupation of the serotonin transporter (SERT) in the thalamus.[94] The estimated median effective dose (ED50) for SERT occupancy hence was 98.1 mg, which was associated with a plasma tramadol level of about 330 ng/ml (1,300 nM).[94] The estimated maximum daily dosage of tramadol of 400 mg (100 mg q.i.d.) would result in as much as 78.7% occupancy of the SERT (in association with a plasma concentration of 1,220 ng/ml or 4,632 nM).[94] This is close to that of SSRIs, which occupy the SERT by 80% or more.[94]

Peak plasma concentrations during treatment with clinical dosages of tramadol have generally been found to be in the range of 70 to 592 ng/ml (266–2,250 nM) for tramadol and 55 to 143 ng/ml (221–573 nM) for desmetramadol.[20] The highest levels of tramadol were observed with the maximum oral daily dosage of 400 mg per day divided into one 100-mg dose every 6 hours (i.e., four 100-mg doses evenly spaced out per day).[20][95] Some accumulation of tramadol occurs with chronic administration; peak plasma levels with the maximum oral daily dosage (100 mg q.i.d.) are about 16% higher and the area-under-the-curve levels 36% higher than following a single oral 100-mg dose.[20] Positron emission tomography imaging studies have reportedly found that tramadol levels are at least four-fold higher in the brain than in plasma.[91][96] Conversely, brain levels of desmetramadol "only slowly approach those in plasma".[91] The plasma protein binding of tramadol is only 4–20%; hence, almost all tramadol in circulation is free, thus bioactive.[97][98][99]

Correspondence to effects

Co-administration of quinidine, a potent CYP2D6 enzyme inhibitor, with tramadol, a combination which results in markedly reduced levels of desmetramadol, was found not to significantly affect the analgesic effects of tramadol in human volunteers.[15][98] However, other studies have found that the analgesic effects of tramadol are significantly decreased or even absent in CYP2D6 poor metabolizers.[15][85] The analgesic effects of tramadol are only partially reversed by naloxone in human volunteers,[15] hence indicating that its opioid action is unlikely the sole factor; tramadol's analgesic effects are also partially reversed by α2-adrenergic receptor antagonists such as yohimbine, the 5-HT3 receptor antagonist ondansetron, and the 5-HT7 receptor antagonists SB-269970 and SB-258719.[20][100] Pharmacologically, tramadol is similar to tapentadol and methadone in that it not only binds to the MOR, but also inhibits the reuptake of serotonin and norepinephrine[8] due to its action on the noradrenergic and serotonergic systems, such as its "atypical" opioid activity.[101]

Tramadol has inhibitory actions on the 5-HT2C receptor. Antagonism of 5-HT2C could be partially responsible for tramadol's reducing effect on depressive and obsessive–compulsive symptoms in patients with pain and co-morbid neurological illnesses.[67] 5-HT2C blockade may also account for its lowering of the seizure threshold, as 5-HT2C knockout mice display significantly increased vulnerability to epileptic seizures, sometimes resulting in spontaneous death. However, the reduction of seizure threshold could be attributed to tramadol's putative inhibition of GABAA receptors at high doses (significant inhibition at 100 μM).[77][60] In addition, desmetramadol is a high-affinity ligand of the DOR, and activation of this receptor could be involved in tramadol's ability to provoke seizures in some individuals, as DOR agonists are well known for inducing seizures.[66]

Nausea and vomiting caused by tramadol are thought to be due to activation of the 5-HT3 receptor via increased serotonin levels.[102] In accordance, the 5-HT3 receptor antagonist ondansetron can be used to treat tramadol-associated nausea and vomiting.[102] Tramadol and desmetramadol themselves do not bind to the 5-HT3 receptor.[102][82]

Pharmacokinetics

Desmetramadol

Tramadol is metabolised in the liver via the cytochrome P450 isozyme CYP2B6, CYP2D6, and CYP3A4, being O- and N-demethylated to five different metabolites. Of these, desmetramadol (O-desmethyltramadol) is the most significant, since it has 200 times the μ-affinity of (+)-tramadol, and furthermore has an elimination half-life of 9 hours, compared with 6 hours for tramadol itself. As with codeine, in the 6% of the population who have reduced CYP2D6 activity (hence reducing metabolism), a reduced analgesic effect is seen. Those with decreased CYP2D6 activity require a dose increase of 30% to achieve the same degree of pain relief as those with a normal level of CYP2D6 activity.[103][104]

Phase II hepatic metabolism renders the metabolites water-soluble, which are excreted by the kidneys. Thus, reduced doses may be used in renal and hepatic impairment.[20]

Its volume of distribution is around 306 L after oral administration and 203 L after parenteral administration.[20]

Chemistry

Tramadol is marketed as a racemic mixture of both R- and S-stereoisomers,[8] because the two isomers complement each other's analgesic activities.[8] The (+)-isomer is predominantly active as an opiate with a higher affinity for the µ-opiate receptor (20 times higher affinity than the (-)-isomer).[105]

Synthesis and stereoisomerism

(1R,2R)-Tramadol.svg (1S,2S)-Tramadol gespiegelt.svg
(1R,2R)-tramadol (1S,2S)-tramadol
(1R,2S)-Tramadol.svg (1S,2R)-Tramadol gespiegelt.svg
(1R,2S)-tramadol (1S,2R)-tramadol

The chemical synthesis of tramadol is described in the literature.[106] Tramadol [2-(dimethylaminomethyl)-1-(3-methoxyphenyl)cyclohexanol] has two stereogenic centers at the cyclohexane ring. Thus, 2-(dimethylaminomethyl)-1-(3-methoxyphenyl)cyclohexanol may exist in four different configurational forms:

  • (1R,2R)-isomer
  • (1S,2S)-isomer
  • (1R,2S)-isomer
  • (1S,2R)-isomer

The synthetic pathway leads to the racemate (1:1 mixture) of (1R,2R)-isomer and the (1S,2S)-isomer as the main products. Minor amounts of the racemic mixture of the (1R,2S)-isomer and the (1S,2R)-isomer are formed as well. The isolation of the (1R,2R)-isomer and the (1S,2S)-isomer from the diastereomeric minor racemate [(1R,2S)-isomer and (1S,2R)-isomer] is realized by the recrystallization of the hydrochlorides. The drug tramadol is a racemate of the hydrochlorides of the (1R,2R)-(+)- and the (1S,2S)-(−)-enantiomers. The resolution of the racemate [(1R,2R)-(+)-isomer / (1S,2S)-(−)-isomer] was described[107] employing (R)-(−)- or (S)-(+)-mandelic acid. This process does not find industrial application, since tramadol is used as a racemate, despite known different physiological effects[108] of the (1R,2R)- and (1S,2S)-isomers, because the racemate showed higher analgesic activity than either enantiomer in animals[109] and in humans.[110]

Detection in biological fluids

Tramadol and desmetramadol may be quantified in blood, plasma, serum, or saliva to monitor for abuse, confirm a diagnosis of poisoning or assist in the forensic investigation of a sudden death. Most commercial opiate immunoassay screening tests do not cross-react significantly with tramadol or its major metabolites, so chromatographic techniques must be used to detect and quantitate these substances. The concentration of desmetramadol in the blood or plasma of a person who has taken tramadol is generally 10–20% those of the parent drug.[111][112][113]

Society and culture

Formulations

Available dosage forms include liquids, syrups, drops, elixirs, effervescent tablets and powders for mixing with water, capsules, tablets including extended-release formulations, suppositories, compounding powder, and injections.[19]

Patent history

The U.S. Food and Drug Administration (FDA) approved tramadol in March 1995, and an extended-release (ER) formulation in September 2005.[114] ER Tramadol was protected by US patents nos. 6,254,887[115] and 7,074,430.[116][117] The FDA listed the patents' expiration as 10 May 2014.[116] However, in August 2009, US District Court for the District of Delaware ruled the patents invalid, a decision upheld the following year by the Court of Appeals for the Federal Circuit. Manufacture and distribution of generic equivalents of Ultram ER in the United States was therefore permitted prior to the expiration of the patents.[118]

Legal status

Effective 18 August 2014, tramadol has been placed into Schedule IV of the federal Controlled Substances Act in the United States.[119][120] Before that, some US states had already classified tramadol as a Schedule IV controlled substance under their respective state laws.[121][122][123]

Tramadol is classified in Schedule 4 (prescription only) in Australia, rather than as a Schedule 8 Controlled Drug (Possession without authority illegal) like most other opioids.[19]

Effective May 2008, Sweden classified tramadol as a controlled substance in the same category as codeine and dextropropoxyphene, but allows a normal prescription to be used.[124]

On 10 June 2014, the United Kingdom's Home Office classified tramadol as a Class C, Schedule 3 controlled drug, but exempted it from the safe custody requirement.[125]

Misuse

Illicit use of the drug is thought to be a major factor in the success of the Boko Haram terrorist organization.[126][127][128] When used at higher doses, the drug "can produce similar effects to heroin."[126] One former member said, "whenever we took tramadol, nothing mattered to us anymore except what we were sent to do because it made us very high and very bold, it was impossible to go on a mission without taking it."[126] Tramadol is also used as a coping mechanism in the Gaza Strip.[129] It is also abused in the United Kingdom , inspiring the title of the TV show Frankie Boyle's Tramadol Nights (2010).[130][131]

From March 2019, the Union Cycliste Internationale (UCI) banned the drug, after riders were using the painkiller to improve their performance.[132][133]

Research

Investigational uses

False findings about sources in nature

In 2013, researchers reported that tramadol was found in relatively high concentrations (1%+) in the roots of the African pin cushion tree (Nauclea latifolia).[142] In 2014, however, it was reported that the presence of tramadol in the tree roots was the result of tramadol having been administered to cattle by farmers in the region:[143] tramadol and its metabolites were present in the animals' excreta, which contaminated the soil around the trees. Therefore, tramadol and its mammalian metabolites were found in tree roots in the far north of Cameroon, but not in the south where it is not administered to farm animals.[143]

A 2014 editorial in Lab Times online contested the notion that tramadol in tree roots was the result of anthropogenic contamination, stating that samples were taken from trees that grew in national parks, where livestock were forbidden; it also quoted researcher Michel de Waard, who stated that "thousands and thousands of tramadol-treated cattle sitting around a single tree and urinating there" would be required to produce the concentrations discovered.[144]

In 2015, radiocarbon analysis confirmed that the tramadol found in N.latifolia roots could not be plant-derived and was of synthetic origin.[145]

Veterinary medicine

Tramadol may be used to treat post-operative, injury-related, and chronic (e.g., cancer-related) pain in dogs and cats as well as rabbits, coatis, many small mammals including rats and flying squirrels, guinea pigs, ferrets, and raccoons.[146]

Pharmacokinetics of tramadol across the species[146]
Species Half-life (h) for parent drug Half-life (h) for desmetramadol Maximum plasma concentration (ng/mL) for parent drug Maximum plasma concentration (ng/mL) for desmetramadol
Camel 3.2 (IM), 1.3 (IV) – 0.44 (IV) –
Cat 3.40 (oral), 2.23 (IV) 4.82 (oral), 4.35 (IV) 914 (oral), 1323 (IV) 655 (oral), 366 (IV)
Dog 1.71 (oral), 1.80 (IV), 2.24 (rectal) 2.18 (oral), 90-5000 (IV) 1402.75 (oral) 449.13 (oral), 90–350 (IV)
Donkey 4.2 (oral), 1.5 (IV) – 2817 (oral) –
Goat 2.67 (oral), 0.94 (IV) – 542.9 (oral) –
Horses 1.29–1.53 (IV), 10.1 (oral) 4 (oral) 637 (IV), 256 (oral) 47 (oral)
Llama 2.54 (IM), 2.12 (IV) 7.73 (IM), 10.4 (IV) 4036 (IV), 1360 (IM) 158 (IV), 158 (IM)

See also

  • Tramadol/paracetamol

References

  1. ↑ 1.0 1.1 1.2 "Tramadol". https://www.drugs.com/international/tramadol.html. 
  2. ↑ "Tramadol Use During Pregnancy". 14 October 2019. https://www.drugs.com/pregnancy/tramadol.html. 
  3. ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 "Tramadol Hydrochloride". The American Society of Health-System Pharmacists. https://www.drugs.com/monograph/tramadol-hydrochloride.html. 
  4. ↑ 4.0 4.1 "Tramadol". MedlinePlus. American Society of Health-System Pharmacists. 1 September 2008. https://www.nlm.nih.gov/medlineplus/druginfo/meds/a695011.html. 
  5. ↑ "Ralivia Product information". 25 April 2012. https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=78458. 
  6. ↑ "Ultram- tramadol hydrochloride tablet, coated". 7 June 2022. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45f59e6f-1794-40a4-8f8b-3a9415924468. 
  7. ↑ "List of nationally authorized medicinal products". European Medicines Agency. 28 January 2021. https://www.ema.europa.eu/en/documents/psusa/tramadol-list-nationally-authorised-medicinal-products-psusa/00003002/202005_en.pdf. 
  8. ↑ 8.0 8.1 8.2 8.3 8.4 Brayfield, A, ed (13 December 2013). "Tramadol Hydrochloride". Martindale: The Complete Drug Reference. Pharmaceutical Press. http://www.medicinescomplete.com/mc/martindale/current/6263-c.htm. 
  9. ↑ 9.0 9.1 "Ultram, Ultram ER (tramadol) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. http://reference.medscape.com/drug/ultram-er-tramadol-343324#showall. 
  10. ↑ 10.0 10.1 "[Pharmacology of tramadol]". Drugs 53 (Suppl 2): 18–24. 1997. doi:10.2165/00003495-199700532-00006. PMID 9190321. 
  11. ↑ 11.0 11.1 11.2 "Australian Label: Tramadol Sandoz 50 mg capsules" (PDF). TGA eBusiness Services. 4 November 2011. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-03844-3. 
  12. ↑ 12.0 12.1 12.2 "Tramadol as an analgesic for mild to moderate cancer pain". Pharmacological Reports 61 (6): 978–992. November–December 2009. doi:10.1016/s1734-1140(09)70159-8. PMID 20081232. 
  13. ↑ 13.0 13.1 British national formulary : BNF 74 (74 ed.). British Medical Association. 2017. pp. 447–448. ISBN 978-0857112989. 
  14. ↑ "Tramadol Pregnancy and Breastfeeding Warnings". https://www.drugs.com/pregnancy/tramadol.html. 
  15. ↑ 15.0 15.1 15.2 15.3 15.4 15.5 15.6 15.7 "Mechanistic and functional differentiation of tapentadol and tramadol". Expert Opinion on Pharmacotherapy 13 (10): 1437–1449. July 2012. doi:10.1517/14656566.2012.696097. PMID 22698264. 
  16. ↑ Analogue-based Drug Discovery. John Wiley & Sons. 2006. p. 528. ISBN 9783527607495. https://books.google.com/books?id=FjKfqkaKkAAC&pg=PA528. Retrieved 3 September 2020. 
  17. ↑ "The Top 300 of 2021". https://clincalc.com/DrugStats/Top300Drugs.aspx. 
  18. ↑ "Tramadol – Drug Usage Statistics". https://clincalc.com/DrugStats/Drugs/Tramadol. 
  19. ↑ 19.00 19.01 19.02 19.03 19.04 19.05 19.06 19.07 19.08 19.09 19.10 Rossi, S, ed (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3. 
  20. ↑ 20.0 20.1 20.2 20.3 20.4 20.5 20.6 20.7 "Clinical pharmacology of tramadol". Clinical Pharmacokinetics 43 (13): 879–923. 2004. doi:10.2165/00003088-200443130-00004. PMID 15509185. 
  21. ↑ "Tramadol for the treatment of fibromyalgia". Expert Review of Neurotherapeutics 15 (5): 469–475. May 2015. doi:10.1586/14737175.2015.1034693. PMID 25896486. 
  22. ↑ "Treatment – Fibromyalgia (NHS)". 20 February 2019. https://www.nhs.uk/conditions/fibromyalgia/treatment/. 
  23. ↑ "Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states". Drugs 46 (2): 313–340. August 1993. doi:10.2165/00003495-199346020-00008. PMID 7691519. 
  24. ↑ "The Appropriate Use of Opioids in the Treatment of Refractory Restless Legs Syndrome". Mayo Clinic Proceedings 93 (1): 59–67. January 2018. doi:10.1016/j.mayocp.2017.11.007. PMID 29304922. "In summary, a number of opioid medications in low dose appear effective in refractory RLS. The risks of opioid use are relatively low, taking into account the much lower doses used for RLS compared with those in patients with pain syndromes. As long as reasonable precautions are taken, the risk-benefit ratio is acceptable and opioids should not be unreasonably withheld from such patients.". 
  25. ↑ "Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017)§". Movement Disorders 33 (7): 1077–1091. July 2018. doi:10.1002/mds.27260. PMID 29756335. https://push-zb.helmholtz-muenchen.de/frontdoor.php?source_opus=54361. Retrieved 13 December 2021. 
  26. ↑ "Long-term use of pramipexole in the management of restless legs syndrome". Sleep Medicine 13 (10): 1280–1285. December 2012. doi:10.1016/j.sleep.2012.08.004. PMID 23036265. "For the purposes of this study, augmentation was defined as earlier onset, increased severity, [increased] duration, or new anatomic distribution of RLS symptoms during treatment.". 
  27. ↑ 27.0 27.1 "Trends in Tramadol: Pharmacology, Metabolism, and Misuse". Anesthesia and Analgesia 124 (1): 44–51. January 2017. doi:10.1213/ANE.0000000000001683. PMID 27861439. 
  28. ↑ 28.0 28.1 28.2 28.3 28.4 "Tramadol in pregnancy and lactation". International Journal of Obstetric Anesthesia 21 (2): 163–167. April 2012. doi:10.1016/j.ijoa.2011.10.008. PMID 22317891. 
  29. ↑ "FDA Drug Safety Communication: FDA evaluating the risks of using the pain medicine tramadol in children aged 17 and younger". FDA Drug Safety and Availability. https://www.fda.gov/Drugs/DrugSafety/ucm462991.htm. 
  30. ↑ Office of the Commissioner. "Press Announcements – FDA statement from Douglas Throckmorton, M.D., deputy center director for regulatory programs, Center for Drug Evaluation and Research, on new warnings about the use of codeine and tramadol in children & nursing mothers" (in en). https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm553285.htm. 
  31. ↑ "FDA Drug Safety Communication: FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children; recommends against use in breastfeeding women". Food and Drug Administration. 9 February 2019. https://www.fda.gov/Drugs/DrugSafety/ucm549679.htm. 
  32. ↑ "Adverse event profile of tramadol in recent clinical studies of chronic osteoarthritis pain". Current Medical Research and Opinion 26 (1): 239–251. January 2010. doi:10.1185/03007990903426787. PMID 19929615. 
  33. ↑ "Tramadol sustained-release capsules". Drugs 66 (2): 223–230. 2006. doi:10.2165/00003495-200666020-00006. PMID 16451094. 
  34. ↑ ""Weak" opioid analgesics. Codeine, dihydrocodeine and tramadol: no less risky than morphine". Prescrire International 25 (168): 45–50. February 2016. PMID 27042732. 
  35. ↑ "Withdrawal syndrome and dependence: tramadol too". Prescrire International 12 (65): 99–100. June 2003. PMID 12825576. 
  36. ↑ 36.0 36.1 36.2 "Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: lessons from tramadol". Biological Psychology 73 (1): 90–99. July 2006. doi:10.1016/j.biopsycho.2006.01.010. PMID 16497429. 
  37. ↑ "Physical dependence on Ultram (tramadol hydrochloride): both opioid-like and atypical withdrawal symptoms occur". Drug and Alcohol Dependence 69 (3): 233–241. April 2003. doi:10.1016/S0376-8716(02)00321-6. PMID 12633909. 
  38. ↑ "Tramadol exposures reported to statewide poison control system". The Annals of Pharmacotherapy 39 (6): 1039–1044. June 2005. doi:10.1345/aph.1e577. PMID 15870139. 
  39. ↑ "Seizures associated with intoxication and abuse of tramadol". Clinical Toxicology 44 (2): 143–146. 1 August 2012. doi:10.1080/1556365050014418. PMID 16615669. 
  40. ↑ "Tramadol poisoning and its management and complications: a scoping review". Annals of Medicine and Surgery 85 (8): 3982–3989. August 2023. doi:10.1097/ms9.0000000000001075. PMID 37554850. 
  41. ↑ 41.0 41.1 "Tramadol, Pharmacology, Side Effects, and Serotonin Syndrome: A Review". Pain Physician 18 (4): 395–400. 14 July 2015. doi:10.36076/ppj.2015/18/395. ISSN 2150-1149. 
  42. ↑ "Tramadol overdose causes seizures and respiratory depression but serotonin toxicity appears unlikely". Clinical Toxicology 53 (6): 545–550. July 2015. doi:10.3109/15563650.2015.1036279. PMID 25901965. 
  43. ↑ "Factors related to seizure in tramadol poisoning and its blood concentration". Journal of Medical Toxicology 7 (3): 183–188. September 2011. doi:10.1007/s13181-011-0168-0. PMID 21735309. 
  44. ↑ "Tramadol poisoning-associated mortality". Journal of Affective Disorders 255: 187. August 2019. doi:10.1016/j.jad.2019.04.069. PMID 30987745. 
  45. ↑ "A review on tramadol toxicity: mechanism of action, clinical presentation, and treatment". Forensic Toxicology 39 (2): 293–310. 24 March 2021. doi:10.1007/s11419-020-00569-0. ISSN 1860-8965. 
  46. ↑ "Tramadol deaths in Northern Ireland: a review of cases from 1996 to 2012". Journal of Forensic and Legal Medicine 23: 32–36. March 2014. doi:10.1016/j.jflm.2014.01.006. PMID 24661703. 
  47. ↑ "Tramadol Deaths in the United Kingdom" (pdf_e). Public Health England. http://www.emcdda.europa.eu/system/files/attachments/3236/Martin%20White-UK-Tramadol%20deaths%20in%20the%20United%20Kingdom%20EMCDDA.pdf_en. 
  48. ↑ "Killing Pain: Tramadol the 'Safe' Drug of Abuse". 22 December 2013. https://www.medpagetoday.com/painmanagement/painmanagement/43554. 
  49. ↑ "Tramadol: The Opioid Crisis for the rest of the World". Dow Jones & Co. 19 October 2016. https://www.wsj.com/articles/tramadol-the-opioid-crisis-for-the-rest-of-the-world-1476887401. 
  50. ↑ "Tramadol prescription patterns in patients followed by general practitioners and orthopedists in Germany in the year 2015". Postgraduate Medicine 130 (1): 37–41. January 2018. doi:10.1080/00325481.2018.1407205. PMID 29157058. 
  51. ↑ "Canada Gazette, Part 2, Volume 155, Number 7: Regulations Amending the Narcotic Control Regulations (Tramadol)". Public Works and Government Services Canada. Government of Canada. 31 March 2021. https://canadagazette.gc.ca/rp-pr/p2/2021/2021-03-31/html/sor-dors43-eng.html. 
  52. ↑ "Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications". The Oncologist 11 (2): 126–135. February 2006. doi:10.1634/theoncologist.11-2-126. PMID 16476833. 
  53. ↑ "CPIC® Guideline for Serotonin Reuptake Inhibitor Antidepressants and CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A – CPIC" (in en-US). https://cpicpgx.org/guidelines/cpic-guideline-for-ssri-and-snri-antidepressants/. 
  54. ↑ "Avoiding serotonin syndrome: the nature of the interaction between tramadol and selective serotonin reuptake inhibitors". The Annals of Pharmacotherapy 46 (12): 1712–1716. December 2012. doi:10.1345/aph.1q748. PMID 23212934. 
  55. ↑ "The effect of ondansetron on the efficacy of postoperative tramadol: a systematic review and meta-analysis of a drug interaction". Anaesthesia 70 (2): 209–218. February 2015. doi:10.1111/anae.12948. PMID 25490944. 
  56. ↑ "Preclinical pharmacology and opioid combinations". Pain Medicine 13 (1): S4-11. March 2012. doi:10.1111/j.1526-4637.2012.01335.x. PMID 22420604. 
  57. ↑ "Tramadol: seizures, serotonin syndrome, and coadministered antidepressants". Psychiatry 6 (4): 17–21. April 2009. PMID 19724727. 
  58. ↑ Top 100 drugs : clinical pharmacology and practical prescribing. Churchill Livingstone Elsevier. 2015. pp. 168–169. ISBN 978-0-7020-5516-4. 
  59. ↑ 60.0 60.1 60.2 "Tramadol hydrochloride: pharmacokinetics, pharmacodynamics, adverse side effects, co-administration of drugs and new drug delivery systems". Biomedicine & Pharmacotherapy 70: 234–238. March 2015. doi:10.1016/j.biopha.2015.01.022. PMID 25776506. 
  60. ↑ "Tramadol". https://www.drugbank.ca/drugs/DB00193. 
  61. ↑ 62.0 62.1 Cite error: Invalid <ref> tag; no text was provided for refs named pmid19027293
  62. ↑ 63.0 63.1 63.2 Cite error: Invalid <ref> tag; no text was provided for refs named pmid27096047
  63. ↑ 64.0 64.1 64.2 64.3 64.4 64.5 64.6 64.7 Cite error: Invalid <ref> tag; no text was provided for refs named pmid8955860
  64. ↑ 65.0 65.1 65.2 Cite error: Invalid <ref> tag; no text was provided for refs named pmid7562497
  65. ↑ 66.0 66.1 66.2 66.3 "Anticonvulsant and proconvulsant effects of tramadol, its enantiomers and its M1 metabolite in the rat kindling model of epilepsy". British Journal of Pharmacology 131 (2): 203–212. September 2000. doi:10.1038/sj.bjp.0703562. PMID 10991912. 
  66. ↑ 67.0 67.1 "The inhibitory effects of tramadol on 5-hydroxytryptamine type 2C receptors expressed in Xenopus oocytes". Anesthesia and Analgesia 98 (5): 1401–6, table of contents. May 2004. doi:10.1213/01.ANE.0000108963.77623.A4. PMID 15105221. 
  67. ↑ "The tramadol metabolite, O-desmethyl tramadol, inhibits 5-hydroxytryptamine type 2C receptors expressed in Xenopus Oocytes". Pharmacology 77 (2): 93–99. 2006. doi:10.1159/000093179. PMID 16679816. 
  68. ↑ "The inhibitory effects of ketamine and pentobarbital on substance p receptors expressed in Xenopus oocytes". Anesthesia and Analgesia 97 (1): 104–10, table of contents. July 2003. doi:10.1213/01.ANE.0000066260.99680.11. PMID 12818951. 
  69. ↑ "The tramadol metabolite O-desmethyl tramadol inhibits substance P-receptor functions expressed in Xenopus oocytes". Journal of Pharmacological Sciences 115 (3): 421–424. 2011. doi:10.1254/jphs.10313sc. PMID 21372504. 
  70. ↑ "Inhibition by tramadol of muscarinic receptor-induced responses in cultured adrenal medullary cells and in Xenopus laevis oocytes expressing cloned M1 receptors". The Journal of Pharmacology and Experimental Therapeutics 299 (1): 255–260. October 2001. PMID 11561087. 
  71. ↑ 72.0 72.1 "The effects of the tramadol metabolite O-desmethyl tramadol on muscarinic receptor-induced responses in Xenopus oocytes expressing cloned M1 or M3 receptors". Anesthesia and Analgesia 101 (1): 180–6, table of contents. July 2005. doi:10.1213/01.ANE.0000154303.93909.A3. PMID 15976229. 
  72. ↑ "The inhibitory effects of tramadol on muscarinic receptor-induced responses in Xenopus oocytes expressing cloned M(3) receptors". Anesthesia and Analgesia 95 (5): 1269–73, table of contents. November 2002. doi:10.1097/00000539-200211000-00031. PMID 12401609. 
  73. ↑ "Inhibitory effects of tramadol on nicotinic acetylcholine receptors in adrenal chromaffin cells and in Xenopus oocytes expressing alpha 7 receptors". British Journal of Pharmacology 136 (2): 207–216. May 2002. doi:10.1038/sj.bjp.0704703. PMID 12010769. 
  74. ↑ 75.0 75.1 Cite error: Invalid <ref> tag; no text was provided for refs named PDSP
  75. ↑ "Modulation of peripheral μ-opioid analgesia by σ1 receptors". The Journal of Pharmacology and Experimental Therapeutics 348 (1): 32–45. January 2014. doi:10.1124/jpet.113.208272. PMID 24155346. 
  76. ↑ 77.0 77.1 77.2 77.3 "The effects of tramadol and its metabolite on glycine, gamma-aminobutyric acidA, and N-methyl-D-aspartate receptors expressed in Xenopus oocytes". Anesthesia and Analgesia 100 (5): 1400–1405. May 2005. doi:10.1213/01.ANE.0000150961.24747.98. PMID 15845694. 
  77. ↑ 78.0 78.1 "Tramadol and its metabolite m1 selectively suppress transient receptor potential ankyrin 1 activity, but not transient receptor potential vanilloid 1 activity". Anesthesia and Analgesia 120 (4): 790–798. April 2015. doi:10.1213/ANE.0000000000000625. PMID 25642661. 
  78. ↑ "The analgesic drug, tramadol, acts as an agonist of the transient receptor potential vanilloid-1". Anesthesia and Analgesia 106 (6): 1890–1896. June 2008. doi:10.1213/ane.0b013e318172fefc. PMID 18499628. 
  79. ↑ 80.0 80.1 80.2 80.3 "Therapeutic potential of monoamine transporter substrates". Current Topics in Medicinal Chemistry 6 (17): 1845–1859. 2006. doi:10.2174/156802606778249766. PMID 17017961. https://zenodo.org/record/1235860. Retrieved 3 September 2020. 
  80. ↑ 81.0 81.1 81.2 Cite error: Invalid <ref> tag; no text was provided for refs named pmid17380034
  81. ↑ 82.0 82.1 82.2 82.3 Cite error: Invalid <ref> tag; no text was provided for refs named pmid26292636
  82. ↑ Cite error: Invalid <ref> tag; no text was provided for refs named pmid10961373
  83. ↑ "µ-Opioid receptor activation by tramadol and O-desmethyltramadol (M1)". Journal of Anesthesia 29 (3): 475–479. June 2015. doi:10.1007/s00540-014-1946-z. PMID 25394761. 
  84. ↑ 85.0 85.1 "Role of active metabolites in the use of opioids". European Journal of Clinical Pharmacology 65 (2): 121–139. February 2009. doi:10.1007/s00228-008-0570-y. PMID 18958460. 
  85. ↑ 86.0 86.1 "Interaction of the central analgesic, tramadol, with the uptake and release of 5-hydroxytryptamine in the rat brain in vitro". British Journal of Pharmacology 105 (1): 147–151. January 1992. doi:10.1111/j.1476-5381.1992.tb14226.x. PMID 1596676. 
  86. ↑ "Actions of tramadol, its enantiomers and principal metabolite, O-desmethyltramadol, on serotonin (5-HT) efflux and uptake in the rat dorsal raphe nucleus". British Journal of Anaesthesia 79 (3): 352–356. September 1997. doi:10.1093/bja/79.3.352. PMID 9389855. 
  87. ↑ 88.0 88.1 "Induction of 5-hydroxytryptamine release by tramadol, fenfluramine and reserpine". European Journal of Pharmacology 349 (2–3): 199–203. May 1998. doi:10.1016/S0014-2999(98)00195-2. PMID 9671098. 
  88. ↑ 89.0 89.1 89.2 "p-Methylthioamphetamine and 1-(m-chlorophenyl)piperazine, two non-neurotoxic 5-HT releasers in vivo, differ from neurotoxic amphetamine derivatives in their mode of action at 5-HT nerve endings in vitro". Journal of Neurochemistry 82 (6): 1435–1443. September 2002. doi:10.1046/j.1471-4159.2002.01073.x. PMID 12354291. 
  89. ↑ "Release studies with rat brain cortical synaptosomes indicate that tramadol is a 5-hydroxytryptamine uptake blocker and not a 5-hydroxytryptamine releaser". European Journal of Pharmacology 370 (1): 23–26. April 1999. doi:10.1016/s0014-2999(99)00123-5. PMID 10323276. 
  90. ↑ 91.0 91.1 91.2 91.3 "Effects of the central analgesic tramadol on the uptake and release of noradrenaline and dopamine in vitro". British Journal of Pharmacology 108 (3): 806–811. March 1993. doi:10.1111/j.1476-5381.1993.tb12882.x. PMID 8467366. 
  91. ↑ "Inhibition of spinal noradrenaline uptake in rats by the centrally acting analgesic tramadol". Biochemical Pharmacology 47 (12): 2289–2293. June 1994. doi:10.1016/0006-2952(94)90267-4. PMID 8031323. 
  92. ↑ "Effects of tramadol stereoisomers on norepinephrine efflux and uptake in the rat locus coeruleus measured by real time voltammetry". British Journal of Anaesthesia 83 (6): 909–915. December 1999. doi:10.1093/bja/83.6.909. PMID 10700792. 
  93. ↑ 94.0 94.1 94.2 94.3 "Occupancy of serotonin transporter by tramadol: a positron emission tomography study with [11C]DASB". The International Journal of Neuropsychopharmacology 17 (6): 845–850. June 2014. doi:10.1017/S1461145713001764. PMID 24423243. 
  94. ↑ "Tramadol Dosage Guide with Precautions". https://www.drugs.com/dosage/tramadol.html. 
  95. ↑ "Differential tramadol and O-desmethyl metabolite levels in brain vs. plasma of mice and rats administered tramadol hydrochloride orally". Journal of Clinical Pharmacy and Therapeutics 27 (2): 99–106. April 2002. doi:10.1046/j.1365-2710.2002.00384.x. PMID 11975693. 
  96. ↑ "Pharmacokinetics, efficacy, and safety of analgesia with a focus on tramadol HCl". The American Journal of Medicine 101 (1A): 47S–53S. July 1996. doi:10.1016/s0002-9343(96)00138-6. PMID 8764760. 
  97. ↑ 98.0 98.1 "The pharmacology of tramadol". Drugs 47 (Suppl 1): 3–7. 1994. doi:10.2165/00003495-199400471-00003. PMID 7517823. 
  98. ↑ "High-performance liquid chromatographic determination of tramadol and its O-desmethylated metabolite in blood plasma. Application to a bioequivalence study in humans". Journal of Chromatography A 949 (1–2): 11–22. March 2002. doi:10.1016/S0021-9673(01)01567-9. PMID 11999728. 
  99. ↑ "Spinal 5-HT7 receptors play an important role in the antinociceptive and antihyperalgesic effects of tramadol and its metabolite, O-Desmethyltramadol, via activation of descending serotonergic pathways". Anesthesiology 112 (3): 696–710. March 2010. doi:10.1097/ALN.0b013e3181cd7920. PMID 20179508. 
  100. ↑ "Antidepressants and pain". Trends in Pharmacological Sciences 27 (7): 348–354. July 2006. doi:10.1016/j.tips.2006.05.004. PMID 16762426. 
  101. ↑ 102.0 102.1 102.2 Cite error: Invalid <ref> tag; no text was provided for refs named pmid16427041
  102. ↑ "CYP2D6 in the metabolism of opioids for mild to moderate pain". Pharmacology 87 (5–6): 274–285. 2011. doi:10.1159/000326085. PMID 21494059. 
  103. ↑ "Applications of CYP450 testing in the clinical setting". Molecular Diagnosis & Therapy 17 (3): 165–184. June 2013. doi:10.1007/s40291-013-0028-5. PMID 23588782. 
  104. ↑ "Tramadol Hydrochloride 50mg Capsules" (in en). UK Electronic Medicines Compendium. January 2016. https://tramadolsale.com/blog/319-tramadol-hydrochloride-50-mg/. 
  105. ↑ Pharmaceutical Substances (4th ed.). Stuttgart (Germany): Thieme-Verlag. 2000. pp. 2085–2086. ISBN 978-1-58890-031-9. ; since 2003 online with biannual actualizations.
  106. ↑ "A Practical Procedure for the Resolution of (+)- and (−)-Tramadol". Organic Process Research & Development 4 (4): 291–294. 2000. doi:10.1021/op000281v. 
  107. ↑ "Chirality: a blueprint for the future". British Journal of Anaesthesia 88 (4): 563–576. April 2002. doi:10.1093/bja/88.4.563. PMID 12066734. 
  108. ↑ "Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol". The Journal of Pharmacology and Experimental Therapeutics 267 (1): 331–340. October 1993. PMID 8229760. 
  109. ↑ "Analgesic efficacy and safety of tramadol enantiomers in comparison with the racemate: a randomised, double-blind study with gynaecological patients using intravenous patient-controlled analgesia". Pain 62 (3): 313–320. September 1995. doi:10.1016/0304-3959(94)00274-I. PMID 8657431. 
  110. ↑ "Pharmacokinetics and dose proportionality of three Tramadol Contramid OAD tablet strengths". Biopharmaceutics & Drug Disposition 28 (6): 323–330. September 2007. doi:10.1002/bdd.561. PMID 17575561. 
  111. ↑ "Fatal unintentional intoxications with tramadol during 1995-2005". Forensic Science International 173 (2–3): 107–111. December 2007. doi:10.1016/j.forsciint.2007.02.007. PMID 17350197. 
  112. ↑ Disposition of Toxic Drugs and Chemicals in Man (11th ed.). Biomedical Publications, Seal Beach, CA. 2017. pp. 2185–2188. ISBN 978-0-692-77499-1. 
  113. ↑ "Tramadol extended-release in the management of chronic pain". Therapeutics and Clinical Risk Management 3 (3): 401–410. June 2007. PMID 18488071. 
  114. ↑ Miller RB, Leslie ST, Malkowska ST, Smith KJ, Wimmer S, Winkler H, Hahn U, Prater DA, "Controlled Release Tramadol", US patent 6254887, issued 3 July 2001
  115. ↑ 116.0 116.1 FDA AccessData entry for Tramadol Hydrochloride . Retrieved 17 August 2009.
  116. ↑ Miller RB, Malkowska ST, Wimmer S, Hahn U, Leslie ST, Smith KJ, Winkler H, Prater DA, "Controlled Release Tramadol Tramadol Formulation", US patent 7074430, issued 11 July 2006
  117. ↑ Purdue Pharma Prods. L.P. v. Par Pharm., Inc., 377 Fed.Appx. 978 (Fed. Cir. 2010).
  118. ↑ "DEA controls tramadol as a schedule IV controlled substance effective August 18, 2014". 2 July 2014. http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2014/07/dea-controls-tramadol-as-a-schedule-iv-controlled-substance-effective-august-18-2014.html. 
  119. ↑ "Federal Registrar". gpo.gov. http://www.gpo.gov/fdsys/pkg/FR-2014-07-02/pdf/2014-15548.pdf. 
  120. ↑ "TRAMADOL (Trade Names: Ultram, Ultracet)". Drug Enforcement Administration (February 2011)
  121. ↑ "Tennessee News: Tramadol and Carisoprodol Now Classified Schedule IV". National Association of Boards of Pharmacy (8 June 2011). Retrieved on 26 December 2012.
  122. ↑ "State of Ohio Board of Pharmacy". Pharmacy.ohio.gov. 18 August 2014. https://pharmacy.ohio.gov/Documents/Notices/Tramadol%20Is%20A%20Schedule%20IV%20Controlled%20Substance%20Effective%20August%2018,%202014.pdf. 
  123. ↑ "Substansen tramadol nu narkotikaklassad på samma sätt som kodein och dextropropoxifen" (in sv). Lakemedelsverket. 14 May 2008. https://lakemedelsverket.se/Alla-nyheter/NYHETER-2008/Substansen-tramadol-nu-narkotikaklassad-pa-samma-satt-som-kodein-och-dextropropoxifen/. 
  124. ↑ "Scheduling of tramadol and exemptions for temazepam prescriptions" (in en). 22 July 2013. https://www.gov.uk/government/consultations/scheduling-of-tramadol-and-exemptions-for-temazepam-prescriptions. 
  125. ↑ 126.0 126.1 126.2 "If you take Tramadol away, you make Boko Haram weak." (in en-GB). 15 March 2019. https://africanarguments.org/2019/03/15/if-you-take-tramadol-away-you-make-boko-haram-weak/. 
  126. ↑ "Drugs for war: Opioid abuse in West Africa" (in en). BBC News. https://www.bbc.com/news/av/world-africa-44325649/tramadol-emboldens-vigilantes-to-fight-boko-haram. 
  127. ↑ The Dangerous Opioid from India. 23 March 2018. https://www.csis.org/npfp/dangerous-opioid-india. Retrieved 18 March 2019. 
  128. ↑ "Gaza's Opioid Problem" (in en-US). The Nation. 7 January 2019. ISSN 0027-8378. https://www.thenation.com/article/gaza-opioid-problem/. 
  129. ↑ "The non-medical use of tramadol in the UK: findings from a large community sample". International Journal of Clinical Practice 68 (9): 1147–1151. September 2014. doi:10.1111/ijcp.12429. PMID 24734958. 
  130. ↑ "Tramadol Abuse & Addiction Causes". 8 August 2018. https://www.ukat.co.uk/opiates/tramadol/. 
  131. ↑ "UCI tests 117 riders for tramadol after painkiller banned in professional cycling" (in en). 22 May 2019. https://www.cyclingweekly.com/news/racing/uci-tests-117-riders-tramadol-painkiller-banned-professional-cycling-424536. 
  132. ↑ "Tramadol could provide performance enhancement for cyclists, study finds". 2 November 2017. https://www.cyclingweekly.com/news/tramadol-found-enhance-cycling-performance-study-finds-357365. 
  133. ↑ "Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy". Neurology 50 (6): 1842–1846. June 1998. doi:10.1212/WNL.50.6.1842. PMID 9633738. 
  134. ↑ "Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy". Journal of Diabetes and Its Complications 14 (2): 65–70. 2000. doi:10.1016/S1056-8727(00)00060-X. PMID 10959067. 
  135. ↑ "Examining the use of tramadol hydrochloride as an antidepressant". Experimental and Clinical Psychopharmacology 19 (2): 123–130. April 2011. doi:10.1037/a0022721. PMID 21463069. 
  136. ↑ "[Treatment of post-herpes zoster pain with tramadol. Results of an open pilot study versus clomipramine with or without levomepromazine]" (in fr). Drugs 53 (Suppl 2): 34–39. 1997. doi:10.2165/00003495-199700532-00008. PMID 9190323. 
  137. ↑ "Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial". Pain 104 (1–2): 323–331. July 2003. doi:10.1016/S0304-3959(03)00020-4. PMID 12855342. 
  138. ↑ "Efficacy and safety of tramadol for premature ejaculation: a systematic review and meta-analysis". Urology 80 (3): 618–624. September 2012. doi:10.1016/j.urology.2012.05.035. PMID 22840860. 
  139. ↑ "The use of tramadol "on-demand" for premature ejaculation: a systematic review". Urology 81 (1): 98–103. January 2013. doi:10.1016/j.urology.2012.08.037. PMID 23102445. 
  140. ↑ "Tramadol as an adjunct to intra-articular local anaesthetic infiltration in knee arthroscopy: a systematic review and meta-analysis". ANZ Journal of Surgery 89 (7–8): 827–832. July 2019. doi:10.1111/ans.14920. PMID 30684306. 
  141. ↑ "Occurrence of the synthetic analgesic tramadol in an African medicinal plant". Angewandte Chemie 52 (45): 11780–11784. November 2013. doi:10.1002/anie.201305697. PMID 24014188. 
  142. ↑ 143.0 143.1 "Tramadol--a true natural product?". Angewandte Chemie 53 (45): 12073–12076. November 2014. doi:10.1002/anie.201406639. PMID 25219922. 
  143. ↑ Who Really did it First? Nature or a Pharmacist? , in Lab Times online; by Nicola Hunt; published 22 September 2014; retrieved 21 November 2015
  144. ↑ "Synthetic Origin of Tramadol in the Environment". Angewandte Chemie 55 (1): 240–243. January 2016. doi:10.1002/anie.201508646. PMID 26473295. 
  145. ↑ 146.0 146.1 "Tramadol use in zoologic medicine". The Veterinary Clinics of North America. Exotic Animal Practice 14 (1): 117–130. January 2011. doi:10.1016/j.cvex.2010.09.005. PMID 21074707. 

Further reading



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Tramadol&oldid=3710928"